1. Home
  2. MODD vs BIVI Comparison

MODD vs BIVI Comparison

Compare MODD & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$3.62

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$2.03

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
BIVI
Founded
1998
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.3M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
MODD
BIVI
Price
$3.62
$2.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
351.2K
10.8M
Earning Date
02-17-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.83
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.82
52 Week High
$6.16
$3.79

Technical Indicators

Market Signals
Indicator
MODD
BIVI
Relative Strength Index (RSI) 51.13 57.05
Support Level $3.13 $1.14
Resistance Level $5.84 $2.30
Average True Range (ATR) 0.53 0.33
MACD 0.06 0.05
Stochastic Oscillator 65.12 73.46

Price Performance

Historical Comparison
MODD
BIVI

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: